| Morphologic Characteristics of Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
|
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
| Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
| Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
|
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
| Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
|
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
|
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Germline mutations in MDS/AML predisposition disorders |
|
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
